SCIENCE ET MEDECINE

Active

Private limited companyfounded 1993active for 32 yearsClos de la Commanderie 3, 1410 Waterloo, BelgiumKBO/BCE: BE 0451.433.347

From the official registers: KBO 32 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

SCIENCE ET MEDECINE has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €91,996 and a net result of -€34,752. Equity is growing by about 2.7% per year across the filed financial years. Its solvency ranks better than 76% of 13,716 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow Report Compare

SCIENCE ET MEDECINEActiveChecked score 93/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 16-12-1993 Normal situation
Legal form: Private limited company
Registered office: Clos de la Commanderie 3, 1410 Waterloo
Activity: Wholesale of pharmaceutical and medical goods NACE 46460
Establishment unit: 2.064.663.608 1410 Waterloo, since 15-12-1993
Financial year end: 31 December
Peppol: Reachable since 27-02-2025

Company details

Who decides

Board

Abdelkader DATOUSSAIDDirector · since 10-10-2023

Board & ownership

How it is doing

93 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.1%

Annual accounts 2025

Gross margin: €2,751; ▲ 115%
Turnover: ≈ €27,000; estimated
Loss: €34,752; ▲ 201%
Equity: €91,996; ▼ 54.4%
Total assets: €127,922; ▼ 54.9%

2025 accounts 50 days early

Filed on 11-06-2026at the National Bank

Financials

Why 93raises riskLoss of €34,752, the second in a row (financial year 2025)lowers riskLiquidity: current ratio 7.52, cash €75,508Size: total assets €127,922Equity €91,996 (71.9% of total assets)Show the evidence

Checked score

Score 2025

93 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 47% of its sector peers (NACE 46, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Strong

Solvency 97+1

equity 71.9% of total assets

Liquidity 100+5

short-term debt 9.7% · cash 59.0%

Profitability 0-16

return on assets -27.2%

Bankruptcy probability, 12 months

0.1% Very low

0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (26,900 companies, NACE 46, micro)

Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.3%▲ +0.1 percentage points vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.2%▼ -0.1 percentage points vs 05-2025 07-2025: 0.3%▲ +0.1 percentage points vs 06-2025 08-2025: 0.3%● unchanged vs 07-2025highest value 09-2025: 0.1%▼ -0.2 percentage points vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026lowest value 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026

Credit of up to €8,000 on 30-day terms is acceptable

Liquidity ample (current ratio 7.52, compared with 4.24 in 2024, above the usual 1.5; short-term debt: 9.7% and cash: 59% of total assets), and 28.1% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro): better than 77% on solvency, 98% on liquidity, 6% on profitability and 9% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Loss of €34,752, the second in a row (financial year 2025)

NBB · annual accounts

Liquidity: current ratio 7.52, cash €75,508

NBB · annual accounts

Size: total assets €127,922

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Equity €91,996 (71.9% of total assets)

NBB · annual accounts

Persistent losses

Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.

NBB · annual accounts 2025

Net result per financial year

1819202122232425

2018 to 2025 · latest year -€34,752

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

50 days early

2024

25 days late

2023

29 days late

2022

28 days late

2021

57 days late

2020

26 days late

2019

62 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 25 days after the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 August (4 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

Key points

Risk: 3 loss-making years in a rowloss financial year 2025 -€34,752 View
Caution: Among the weakest 8% on net resultsector median €5,660 · 13,722 companies -€34,752 View
Caution: Equity fell in 2025from €201,748 to €91,996 ▼ 54.4% View

Documents

Key facts about SCIENCE ET MEDECINE

What is the company number of SCIENCE ET MEDECINE?: 0451.433.347. In Belgium the VAT number is the company number with BE in front: BE 0451.433.347.
Where is SCIENCE ET MEDECINE based?: The registered office is at Clos de la Commanderie 3, 1410 Waterloo.Company details
What does SCIENCE ET MEDECINE do?: According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of SCIENCE ET MEDECINE?: Private limited company (BV).
When was SCIENCE ET MEDECINE founded?: On 16-12-1993.
Is SCIENCE ET MEDECINE still active?: Yes, SCIENCE ET MEDECINE is an active enterprise in the KBO register.
What is the turnover of SCIENCE ET MEDECINE?: ≈ €27,000 in financial year 2025. Estimated from the gross margin of €2,751: probably between €15,000 and €110,000, based on 41 comparable companies, NACE 464. A rough estimate. In financial year 2024 turnover was €33,657.Financials
Is SCIENCE ET MEDECINE profitable?: In financial year 2025, SCIENCE ET MEDECINE made a loss of €34,752.
Where can I find the annual accounts of SCIENCE ET MEDECINE?: SCIENCE ET MEDECINE filed 32 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of SCIENCE ET MEDECINE due?: By 31-07-2027, for financial year 2026.Timeline